Dual Targeting of FGFR4 and PI3K-mTOR Suppresses Tumor-Associated Phenotypes in Pancreatic Ductal Adenocarcinoma.

doi:10.3390/ijms27177722

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Dual Targeting of FGFR4 and PI3K-mTOR Suppresses Tumor-Associated Phenotypes in Pancreatic Ductal Adenocarcinoma.

International journal of molecular sciences - 28 Aug 2026

Goode Joseph A, Harris Savannah A, Altomare Deborah A

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) is characterized by extensive adaptive signaling plasticity and metabolic reprogramming that contribute to therapeutic resistance. While the PI3K-mTOR pathway is a central regulator of these processes, the role of the FGF19-FGFR4 axis and its interaction with PI3K-mTOR signaling remains incompletely defined in PDAC. This study investigated whether co-targeting FGFR4 and...

Read the complete abstract on PubMed

Topics

Humans
TOR Serine-Threonine Kinases
Receptor, Fibroblast Growth Factor, Type 4
Carcinoma, Pancreatic Ductal
Cell Line, Tumor
Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Signal Transduction

Pancreatic Neoplasms

Phenotype

Apoptosis

Triazines

Gene Expression Regulation, Neoplastic

Cell Proliferation

Morpholines

Source

Open in PubMed Open full text

Identifiers

PMID: 42737619
DOI: 10.3390/ijms27177722
PMCID: PMC13566174

Genes

FGFR4
FGF19

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dual Targeting of FGFR4 and PI3K-mTOR Suppresses Tumor-Associated Phenotypes in Pancreatic Ductal Adenocarcinoma.PMID 42737619Read ↗

Pathway-selective strategies reveal specific PI3K–mTOR inhibitors as key partners in KRAS G12D-targeted therapySemantic proximity Read ↗

A Genome-scale CRISPR Screen Identifies the ERBB and mTOR Signaling Networks as Key Determinants of Response to PI3K Inhibition in Pancreatic CancerSemantic proximity Read ↗

KRAS Pathway-based Therapeutic Approaches in Pancreatic Cancer.Semantic proximity Read ↗

Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers.Semantic proximity Read ↗

Loss of FGFR4 promotes the malignant phenotype of PDAC.Semantic proximity Read ↗

PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?Semantic proximity Read ↗

Altered PI3K and ERK/MAPK Signaling in KRASG12R-Driven Pancreatic Cancer Presents Opportunities for Precision Therapy.Semantic proximity Read ↗

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancerSemantic proximity Read ↗

MTOR inhibitor-based combination therapies for pancreatic cancerSemantic proximity Read ↗

K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas.Semantic proximity Read ↗

Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer.Semantic proximity Read ↗

Cell-specific models reveal conformation-specific RAF inhibitor combinations that synergistically inhibit ERK signaling in pancreatic cancer cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.